Just Diagnosed

Dr. Rosalyn Juergens, McMaster University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.

[powerpress]

Dr. Ravi Salgia from the University of Chicago discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.

[powerpress]

Dr. David Spigel, Sarah Cannon Cancer Center, gives his view on more widespread availability of new mutation tests.

[powerpress]

Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

[powerpress]

Dr. Phil Bonomi, from Rush University, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

[powerpress]

Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.

[powerpress]

Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread availability of new mutation tests under the Canadian health care system.

[powerpress]